Mass spectrometry-based proteomic study makes high-density lipoprotein a biomarker for atherosclerotic vascular disease

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Chang, Chiz Tzung ^a,b   Yang, Chao Yuh ^b,c   Tsai, Fuu Jen ^b   Lin, Shih Yi ^a,b   Chen, Chao Jung ^b,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; APOLIPOPROTEIN; BIOLOGICAL MARKER;

ARTICLE; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ISOLATION AND PURIFICATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; PATHOLOGY; PROCEDURES;

APOLIPOPROTEINS; ATHEROSCLEROSIS; BIOMARKERS; HUMANS; LIPOPROTEINS, HDL; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84930965986     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/164846     Document Type: Article

References (99)

1. P. Barter, J. Kastelein, A. Nunn et al., "High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions," Atherosclerosis, vol. 168, no. 2, pp. 195-211, 2003.
2. K.-A. Rye and P. J. Barter, "Regulation of high-density lipoprotein metabolism," Circulation Research, vol. 114, no. 1, pp. 143-156, 2014.
3. W. B. Kannel, "High-density lipoproteins: epidemiologic profile and risks of coronary artery disease," American Journal of Cardiology, vol. 52, no. 4, pp. 9B-12B, 1983.
4. A. V. Khera, M. Cuchel, M. de la Llera-Moya et al., "Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis,"The New England Journal ofMedicine, vol. 364, no. 2, pp. 127-135, 2011.
5. D. Bailey, I. Ruel, A. Hafiane et al., "Analysis of lipid transfer activity between model nascent HDL particles and plasma lipoproteins: implications for current concepts of nascent HDL maturation and genesis," The Journal of Lipid Research, vol. 51, no. 4, pp. 785-797, 2010.
6. Y. Huang, Z. Wu, M. Riwanto et al., "Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex," The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3815-3828, 2013.
7. C. Li, W. Zhang, F. Zhou et al., "Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis," PLoS ONE, vol. 8, no. 10, Article ID e77049, 2013.
8. T. Vaisar, P. Mayer, E. Nilsson, X.-Q. Zhao, R. Knopp, and B. J. Prazen, "HDL in humans with cardiovascular disease exhibits a proteomic signature," Clinica Chimica Acta, vol. 411, no. 13-14, pp. 972-979, 2010.
9. C.-T. Chang, H.-Y. Liao, C.-M. Chang et al., "Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease," Clinica Chimica Acta, vol. 420, pp. 69-75, 2013.
10. M. Holzer, M. Gauster, T. Pfeifer et al., "Protein carbamylation renders high-density lipoprotein dysfunctional," Antioxidants and Redox Signaling, vol. 14, no. 12, pp. 2337-2346, 2011.
11. R. J. Havel, H. A. Eder, and J. H. Bragdon, "The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum,"The Journal of Clinical Investigation, vol. 34, no. 9, pp. 1345-1353, 1955.
12. Y. Abe, M. Fornage, C.-Y. Yang et al., "L5, the most electronegative subfraction of plasma LDL, induces endothelial vascular cell adhesion molecule 1 and CXC chemokines, which mediate mononuclear leukocyte adhesion," Atherosclerosis, vol. 192, no. 1, pp. 56-66, 2007.
13. A. S. Shah, L. Tan, J. L. Long, and W. S. Davidson, "Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond," Journal of Lipid Research, vol. 54, no. 10, pp. 2575-2585, 2013.
14. T. Vaisar, S. Pennathur, P. S. Green et al., "Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL," The Journal of Clinical Investigation, vol. 117, no. 3, pp. 746-756, 2007.
15. B. J. Arsenault, I. Lemieux, J.-P.Després et al., "HDL particle size and the risk of coronary heart disease in apparently healthymen and women: the EPIC-Norfolk prospective population study," Atherosclerosis, vol. 206, no. 1, pp. 276-281, 2009.
16. J.-Y. Hsieh, C.-T. Chang, M. T. Huang et al., "Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein fromnormal adults," Analytical Chemistry, vol. 85, no. 23, pp. 11440-11448, 2013.
17. D. T. A. Eisenberg, C.W. Kuzawa, and M. G.Hayes, "Worldwide allele frequencies of the human apolipoprotein E gene: climate, local adaptations, and evolutionary history," American Journal of Physical Anthropology, vol. 143, no. 1, pp. 100-111, 2010.
18. R. W. Mahley, T. L. Innerarity, S. C. Rall Jr., and K. H. Weisgraber, "Plasma lipoproteins: apolipoprotein structure and function," Journal of Lipid Research, vol. 25, no. 12, pp. 1277-1294, 1984.
19. J.-F. Mauger, P. Couture, N. Bergeron, and B. Lamarche, "Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism," Journal of Lipid Research, vol. 47, no. 6, pp. 1212-1218, 2006.
20. D. El-Gamal, M. Holzer, M. Gauster et al., "Cyanate is a novel inducer of endothelial ICAM-1 expression," Antioxidants and Redox Signaling, vol. 16, no. 2, pp. 129-137, 2012.
21. K.-A. Rye, N. J. Hime, and P. J. Barter, "The influence of cholesteryl ester transfer protein on the composition, size, and structure of spherical, reconstituted high density lipoproteins," The Journal of Biological Chemistry, vol. 270, no. 1, pp. 189-196, 1995.
22. L. Dumont, T. Gautier, J.-P. de Barros et al., "Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI," The Journal of Biological Chemistry, vol. 280, no.45, pp. 38108-38116, 2005.
23. Y. Shen, A. Lookene, S. Nilsson, andG.Olivecrona, "Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase," Journal of Biological Chemistry, vol. 277, no. 6, pp. 4334-4342, 2002.
24. M. de la Llera Moya, F. C. McGillicuddy, C. C. Hinkle et al., "Inflammation modulates human HDL composition and function in vivo," Atherosclerosis, vol. 222, no. 2, pp. 390-394, 2012.
25. M. Holzer, R. Birner-Gruenberger, T. Stojakovic et al., "Uremia alters HDL composition and function," Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1631-1641, 2011.
26. M. Holzer, P. Wolf, M. Inzinger et al., "Anti-psoriatic therapy recovers high-density lipoprotein composition and function," Journal of InvestigativeDermatology, vol. 134, no. 3,pp. 635-642, 2014.
27. P.-H. Groop,M. C.Thomas,M. Rosengard-Bärlund et al., "HDL composition predicts new-onset cardiovascular disease in patients with type 1 diabetes," Diabetes Care, vol. 30, no. 10, pp. 2706-2707, 2007.
28. N. Shuhei, S. Söderlund, M. Jauhiainen, and M.-R. Taskinen, "Effect of HDL composition and particle size on the resistance of HDL to the oxidation," Lipids in Health and Disease, vol. 9, article 104, 2010.
29. C. Esau, S. Davis, S. F. Murray et al., "miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting," Cell Metabolism, vol. 3, no. 2, pp. 87-98, 2006.
30. K. J. Rayner, Y. Suárez, A. Dávalos et al., "MiR-33 contributes to the regulation of cholesterol homeostasis," Science, vol. 328, no. 5985, pp. 1570-1573, 2010.
31. M. V. Pahl, Z. Ni, L. Sepassi, H. Moradi, and N. D. Vaziri, "Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD)," Nephrology Dialysis Transplantation, vol. 24, no. 8, pp. 2541-2546, 2009.
32. D. M. Shih, Y.-R. Xia, X.-P. Wang et al., "Combined serum paraoxonase knockout/apolipoprotein E knockoutmice exhibit increased lipoprotein oxidation and atherosclerosis," The Journal of Biological Chemistry, vol. 275, no. 23, pp. 17527-17535, 2000.
33. M. A. Kennedy, G. C. Barrera, K. Nakamura et al., "ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation," Cell Metabolism, vol. 1, no. 2, pp. 121-131, 2005.
34. N. Terasaka, M. Westerterp, J. Koetsveld et al., "ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 11, pp. 2219-2225, 2010.
35. L. Yvan-Charvet, C. Welch, T. A. Pagler et al., "Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions," Circulation, vol. 118, no. 18, pp. 1837-1847, 2008.
36. J. K. Kruit, N. Wijesekara, C. Westwell-Roper et al., "Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired beta-cell function," Diabetes, vol. 61, no. 3, pp. 659-664, 2012.
37. I. S. Yuhanna, Y. Zhu, B. E. Cox et al., "High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase," Nature Medicine, vol. 7, no. 7, pp. 853-857, 2001.
38. G. Assmann and J.-R. Nofer, "Atheroprotective effects of highdensity lipoproteins," Annual Review of Medicine, vol. 54, pp. 321-341, 2003.
39. D. Seetharam, C. Mineo, A. K. Gormley et al., "High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I," Circulation Research, vol. 98, no. 1, pp. 63-72, 2006.
40. T. F. Lüscher, U. Landmesser, A. von Eckardstein, and A. M. Fogelman, "High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target," Circulation Research, vol. 114, no. 1, pp. 171-182, 2014.
41. L. Á. Cuellar, E. D. Prieto, L. V. Cabaleiro, and H. A. Garda, "Apolipoprotein A-I configuration and cell cholesterol efflux activity of discoidal lipoproteins depend on the reconstitution process," Biochimica et Biophysica Acta, vol. 1841, no. 1, pp. 180-189, 2014.
42. M. Krieger, "Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI," Annual Review of Biochemistry, vol. 68, pp. 523-558, 1999.
43. N. Y. Gbandjaba, N. Ghalim, M. Hassar et al., "Paraoxonase activity in healthy, diabetic, and hemodialysis patients," Clinical Biochemistry, vol. 45, no. 6, pp. 470-474, 2012.
44. T. van Himbergen, M. Roest, F. de Waart et al., "Paraoxonase genotype, LDL-oxidation and carotid atherosclerosis in male life-long smokers," Free Radical Research, vol. 38, no. 6, pp. 553-560, 2004.
45. L. D. Cacciagiú, A. I. González, L. G. Rosso et al., "HDLassociated enzymes and proteins in hemodialysis patients," Clinical Biochemistry, vol. 45, no. 3, pp. 243-248, 2012.
46. M.Madjid,M. Ali, and J. T.Willerson, "Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature," Texas Heart Institute Journal, vol. 37, no. 1, pp. 25-39, 2010.
47. A. Matsuzawa, K. Hattori, J. Aoki, H. Arai, and K. Inoue, "Protection against oxidative stress-induced cell death by intracellular platelet-activating factor-acetylhydrolase II," Journal of Biological Chemistry, vol. 272, no. 51, pp. 32315-32320, 1997.
48. A. D. Mooradian, "Dyslipidemia in type 2 diabetes mellitus," Nature Clinical Practice Endocrinology and Metabolism, vol. 5, no. 3, pp. 150-159, 2009.
49. J. J. Chillarón, J. A. Flores le-Roux, D. Benaiges, and J. Pedro-Botet, "Type 1 diabetes,metabolic syndrome and cardiovascular risk," Metabolism: Clinical and Experimental, vol. 63, no. 2, pp. 181-187, 2014.
50. M. J. Cziraky, K. E. Watson, R. L. Talbert, and P. Stella, "Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting," Journal of Managed Care Pharmacy, vol. 14, supplement 8, pp. S3-S28, 2008.
51. D. J. Gordon, J. L. Probstfield, R. J. Garrison et al., "Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies," Circulation, vol. 79, no. 1, pp. 8-15, 1989.
52. M. Briel, I. Ferreira-Gonzalez, J. J. You et al., "Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis," British Medical Journal, vol. 338, no. 7693, article b92, 2009.
53. L. Calabresi and G. Franceschini, "Lecithin: cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans," Trends in Cardiovascular Medicine, vol. 20, no. 2, pp. 50-53, 2010.
54. J. C. van Capelleveen, H. B. Brewer, J. J. P. Kastelein, and G. K. Hovingh, "Novel therapies focused on the high-density lipoprotein particle," Circulation Research, vol. 114, no. 1, pp. 193-204, 2014.
55. S. Stukas, J. Robert, and C. L. Wellington, "High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease," Cell Metabolism, vol. 19, no. 4, pp. 574-591, 2014.
56. H. Berrougui, S. Loued, and A. Khalil, "Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages," Free Radical Biology and Medicine, vol. 52, no. 8, pp. 1372-1381, 2012.
57. M. Roest, T. M. van Himbergen, A. B. Barendrecht, P. H. M. Peeters, Y. T. van der Schouw, and H. A. M. Voorbij, "Genetic and environmental determinants of the PON-1 phenotype," European Journal of Clinical Investigation, vol. 37, no. 3, pp. 187-196, 2007.
58. N. D. Vaziri, "Causes of dysregulation of lipid metabolism in chronic renal failure," Seminars in Dialysis, vol. 22, no. 6, pp. 644-651, 2009.
59. N. A. Karp and K. S. Lilley, "Investigating sample pooling strategies for DIGE experiments to address biological variability," Proteomics, vol. 9, no. 2, pp. 388-397, 2009.
60. P. J. Barter, S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman, "Antiinflammatory properties of HDL," Circulation Research, vol. 95, no. 8, pp. 764-772, 2004.
61. D. Chelius and P. V. Bondarenko, "Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry," Journal of Proteome Research, vol. 1, no. 4, pp. 317-323, 2002.
62. L. Zheng, B. Nukuna, M.-L. Brennan et al., "Apolipoprotein AI is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease,"The Journal of Clinical Investigation, vol. 114, no. 4, pp. 529-541, 2004.
63. S. Arora, M. Husain, D. Kumar et al., "Human immunodeficiency virus downregulates podocyte apoE expression," American Journal of Physiology: Renal Physiology, vol. 297, no. 3, pp. F653-F661, 2009.
64. M. D. Sury, J.-X. Chen, and M. Selbach, "The SILAC fly allows for accurate protein quantification in vivo," Molecular and Cellular Proteomics, vol. 9, no. 10, pp. 2173-2183, 2010.
65. M. Krüger, M. Moser, S. Ussar et al., "SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function," Cell, vol. 134, no. 2, pp. 353-364, 2008.
66. T. Geiger, J. R. Wisniewski, J. Cox et al., "Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics," Nature Protocols, vol. 6, no. 2, pp. 147-157, 2011.
67. A. Jaleel, G. C. Henderson, B. J.Madden et al., "Identification of de novo synthesized and relatively older proteins: aAccelerated oxidative damage to de novo synthesized apolipoprotein A-1 in type 1 diabetes," Diabetes, vol. 59, no. 10, pp. 2366-2374, 2010.
68. A. Lapolla, M. Brioschi, C. Banfi et al., "Nonenzymatically glycated lipoprotein ApoA-I in plasma of diabetic and nephropathic patients," Annals of the New York Academy of Sciences, vol. 1126, pp. 295-299, 2008.
69. N. Tang, P. Tornatore, and S. R. Weinberger, "Current developments in SELDI affinity technology," Mass Spectrometry Reviews, vol. 23, no. 1, pp. 34-44, 2004.
70. M. F. Brodde, S. J. A. Korporaal, G. Herminghaus et al., "Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids," Atherosclerosis, vol. 215, no. 2, pp. 374-382, 2011.
71. J. D. Otvos, "Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy," Clinical Laboratory, vol. 48, no. 3-4, pp. 171-180, 2002.
72. P. J. Blanche, E. L.Gong, T. M. Forte, andA.V.Nichols, "Characterization of human high-density lipoproteins by gradient gel electrophoresis," Biochimica et Biophysica Acta, vol. 665, no. 3, pp. 408-419, 1981.
73. R. S. Rosenson, H. B. Brewer Jr., M. J. Chapman et al., "HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events," Clinical Chemistry, vol. 57, no. 3, pp. 392-410, 2011.
74. J.-Y. Lee, L. Lanningham-Foster, E. Y. Boudyguina et al., "Preβ high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice," Journal of Lipid Research, vol. 45, no. 4, pp. 716-728, 2004.
75. B. F. Asztalos, C. H. Sloop, L. Wong, and P. S. Roheim, "Twodimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations," Biochimica et Biophysica Acta, vol. 1169, no. 3, pp. 291-300, 1993.
76. P. Davidsson, J. Hulthe, B. Fagerberg, and G. Camejo, "Proteomics of apolipoproteins and associated proteins fromplasma high-density lipoproteins," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 2, pp. 156-163, 2010.
77. T. Vaisar, "Proteomics investigations of HDL: challenges and promise,"CurrentVascular Pharmacology, vol. 10,no. 4, pp.410-421, 2012.
78. I. Jorge, E. Burillo, R. Mesa et al., "The human HDL proteome displays high inter-individual variability and is altered dynamically in response to angioplasty-induced atheroma plaque rupture," Journal of Proteomics, vol. 106, pp. 61-73, 2014.
79. A. Mangé, A. Goux, S. Badiou et al., "Hdl proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography-tandem mass spectrometry approach," PLoS ONE, vol. 7, no. 3,Article ID e34107, 2012.
80. K. Alwaili, D. Bailey, Z. Awan et al., "The HDL proteome in acute coronary syndromes shifts to an inflammatory profile," Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1821, no. 3, pp. 405-415, 2012.
81. T. Weichhart, C. Kopecky, M. Kubicek et al., "Serum amyloid A in uremic HDL promotes inflammation," Journal of the American Society of Nephrology, vol. 23,no. 5, pp. 934-947, 2012.
82. J. Cubedo, T. Padró, R. Alonso, J. Cinca, P. Mata, and L. Badimon, "Differential proteomic distribution of TTR (prealbumin) forms in serum and HDL of patients with high cardiovascular risk," Atherosclerosis, vol. 222, no. 1, pp. 263-269, 2012.
83. K. Conde-Knape, A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter, "Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase," Journal of Lipid Research, vol. 43, no. 12, pp. 2136-2145, 2002.
84. M. S. Wroblewski, J. T. Wilson-Grady, M. B. Martinez et al., "A functional polymorphism of apolipoprotein C1 detected by mass spectrometry," FEBS Journal, vol. 273, no. 20, pp. 4707-4715, 2006.
85. D. Moore, C. McNeal, and R. Macfarlane, "Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease," Biochemical and Biophysical Research Communications, vol. 404, no. 4, pp. 1034-1038, 2011.
86. C. J. Fielding, V. G. Shore, and P. E. Fielding, "Lecithin: cholesterol acyltransferase: effects of substrate composition upon enzyme activity," Biochimica et Biophysica Acta, vol. 270, no. 4, pp. 513-518, 1972.
87. B. Shao, M. N. Oda, C. Bergt et al., "Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I," The Journal of Biological Chemistry, vol. 281, no. 14, pp. 9001-9004, 2006.
88. B. Shao, G. Cavigiolio,N. Brot, M. N. Oda, and J.W.Heinecke, "Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 34, pp. 12224-12229, 2008.
89. A. Lapolla, M. Brioschi, C. Banfi et al., "On the search for glycated lipoprotein ApoA-I in the plasma of diabetic and nephropathic patients," Journal of Mass Spectrometry, vol. 43, no. 1, pp. 74-81, 2008.
90. A. Hoang, A. J. Murphy, M. T. Coughlan et al., "Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties," Diabetologia, vol. 50, no. 8, pp. 1770-1779, 2007.
91. C. C. Hedrick, S. R. Thorpe, M.-X. Fu et al., "Glycation impairs high-density lipoprotein function," Diabetologia, vol. 43, no. 3, pp. 312-320, 2000.
92. A. P. MacHado, R. S. Pinto, Z. P. Moysés, E. R. Nakandakare, E. C. R. Quintão, and M. Passarelli, "Aminoguanidine and metformin prevent the reduced rate of HDL-mediated cell cholesterol efflux induced by formation of advanced glycation end products," International Journal of Biochemistry and Cell Biology, vol. 38, no. 3, pp. 392-403, 2006.
93. E. Nobécourt, F. Tabet, G. Lambert et al., "Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 766-772, 2010.
94. N. Terasaka, N. Wang, L. Yvan-Charvet, and A. R. Tall, "Highdensity lipoprotein protects macrophages from oxidized lowdensity lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15093-15098, 2007.
95. R. A. Koeth, K. Kalantar-Zadeh, Z.Wang, X. Fu,W.H.W. Tang, and S. L. Hazen, "Protein carbamylation predicts mortality in ESRD," Journal of the American Society of Nephrology, vol. 24, no. 5, pp. 853-861, 2013.
96. J.Cubedo, T. Padró, and L. Badimon, "Glycoproteome of human apolipoprotein A-I: N-and O-glycosylated forms are increased in patients with acute myocardial infarction," Translational Research, vol. 164, no. 3, pp. 209-222, 2014.
97. Y. Xiao, L. Guo, and Y. Wang, "A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues," Molecular and Cellular Proteomics, vol. 13, no. 4, pp. 1065-1075, 2014.
98. Y. Tan, T. R. Liu, S. W. Hu et al., "Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions," PLoS ONE, vol. 9, no. 4, Article ID e94264, 2014.
99. M. Riwanto, L. Rohrer, B. Roschitzki et al., "Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling," Circulation, vol. 127, no. 8, pp. 891-904, 2013.